Using plasma proteomics to understand Alzheimer’s and other brain diseases

Using plasma proteomics to understand Alzheimer’s and other brain diseases

The plasma proteome presents a goldmine of information that can be used to develop diagnostic tests and identify novel drug targets. In this webinar, our expert speaker Dr. Keenan Walker describes his research into understanding the proteins, protein networks and biological pathways involved in age-related neurodegenerative diseases and vascular cognitive impairment.

Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebrospinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.

Learn about:

  • Proteins most strongly implicated in dementia risk
  • How combining proteomics with neuroimaging to provide new insights into cerebral small vessel disease
  • The process of nominating potentially casual proteins and genetically validating biomarkers

Image of Dr Keenan Walker

Keenan Walker, PhD

Chief, Multimodal Imaging of Neurodegenerative Disease (MIND)
National Institute on Aging

Keenan Walker, PhD, is an investigator at the National Institute on Aging Intramural Research Program and Chief of the Multimodal Imaging of Neurodegenerative Disease (MIND) unit. Dr. Walker’s current research program focuses on understanding the role of abnormal immune function in Alzheimer’s disease and late-life cognitive decline.

Using plasma proteomics to understand Alzheimer’s and other brain diseases

A presentation by Keenan Walker, PhD

Share with colleagues

More webinars

WebinarUtilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure 

Plasma proteomics is a powerful approach for discovering novel protein biomarkers of drug toxicity in various disease contexts. One such biomarker in cardiovascular disease is apolipoprotein M (ApoM), which plays a crucial role in lipid metabolism and transport and is known to have both anti-inflammatory and cardioprotective effects in the body. Studying ApoM using proteomics requires various approaches to understand its expression, modifications, interactions, and functions in the proteome.

Learn more

WebinarProteomics for precision neuroscience: The power of protein analysis

This webcast highlights how academic, industry and government researchers are directly measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.

Learn more

WebinarCorrelation of a nonalcoholic steatohepatitis proteomic test with clinical outcomes

In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.

Learn more

Explore webinars in our interactive viewer